2020
The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts
Lundsten S, Spiegelberg D, Raval NR, Nestor M. The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 980-990. PMID: 31912256, PMCID: PMC7075859, DOI: 10.1007/s00259-019-04673-1.Peer-Reviewed Original ResearchConceptsComplete remissionToxicity profileNeuroendocrine tumorsSomatostatin receptorsCombination treatmentHistological analysisFavorable toxicity profileBetter therapeutic resultsDose-limiting organHeat shock protein 90 inhibitorShock protein 90 inhibitorsNeuroendocrine tumor xenograftsMonotherapy groupGlomerular injuryUnwanted side effectsCombination groupTherapeutic resultsTherapeutic effectTumor xenograftsSide effectsTumor uptakeRemissionXenograftsTumorsHSP70 upregulation
2019
350P Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173)
Wesolowski R, Brufsky A, Chambers M, Bhattacharya S, Lustberg M, VanDeusen J, Sardesai S, Williams N, Noonan A, Phelps M, Grever M, Stephens J, Carson W, Ramaswamy B. 350P Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple negative breast cancer (NCT02474173). Annals Of Oncology 2019, 30: v126. DOI: 10.1093/annonc/mdz242.045.Peer-Reviewed Original ResearchTriple-negative breast cancerOverall response rateNegative breast cancerBreast cancerDay 1Cancer Therapy Evaluation ProgramCycle 1Clinical benefit rateCommon grade 3Dose level 1Dose-expansion studyHigher adverse eventsPhase Ib studySchedule of paclitaxelAcceptable safety profileProgression-free survivalHeat shock protein 90 inhibitorShock protein 90 inhibitorsNational Cancer InstituteEvaluable ptsPaclitaxel hypersensitivityStudy regimenAdverse eventsMethods PatientsSafety profile
2017
Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173).
Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Poi M, Wilson D, Grever M, Stephens J, Puhalla S, Mathew A, Carson W, Ramaswamy B. Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). Journal Of Clinical Oncology 2017, 35: tps1127-tps1127. DOI: 10.1200/jco.2017.35.15_suppl.tps1127.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerDay 1Hormone receptor-positive breast cancerReceptor-positive breast cancerPhase Ib studyPhase II doseProgression-free survivalPositive breast cancerOverall response rateHeat shock protein 90 inhibitorNegative breast cancerCycle 1Shock protein 90 inhibitorsPoor outcomeStandard doseAndrogen receptorHsp90 client proteinsHeat shock protein 90Ib studyResponse durationToxicity profilePaclitaxel resistanceClient proteinsDay 7
2009
A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status
Sequist L, Gettinger S, Natale R, Martins R, Lilenbaum R, Jänne P, Gray J, Samuel T, Grayzel D, Lynch T. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status. Journal Of Clinical Oncology 2009, 27: 8073-8073. DOI: 10.1200/jco.2009.27.15_suppl.8073.Peer-Reviewed Original ResearchNon-small cell lung cancerPhase II trialIPI-504Anti-tumor activityStable diseaseStage IIIBII trialPartial responseStage IV non-small cell lung cancerAdvanced non-small cell lung cancerCommon related adverse eventsIndependent radiology reviewAntitumor activityRelated adverse eventsCell lung cancerEGFR mutation analysisEGFR mutation statusHeat shock protein 90 inhibitorNSCLC cell linesShock protein 90 inhibitorsMurine xenograft modelCohort expansionEligible patientsNovel Hsp90 inhibitorPrior therapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply